KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Total Debt (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Total Debt data on record, last reported at $572.1 million in Q4 2025.

  • For Q4 2025, Total Debt fell 13.8% year-over-year to $572.1 million; the TTM value through Dec 2025 reached $572.1 million, down 13.8%, while the annual FY2025 figure was $572.1 million, 13.8% down from the prior year.
  • Total Debt reached $572.1 million in Q4 2025 per EBS's latest filing, down from $663.1 million in the prior quarter.
  • Across five years, Total Debt topped out at $1.0 billion in Q3 2022 and bottomed at $446.5 million in Q4 2023.
  • Average Total Debt over 5 years is $657.4 million, with a median of $663.7 million recorded in 2024.
  • Peak YoY movement for Total Debt: tumbled 44.59% in 2022, then surged 49.4% in 2025.
  • A 5-year view of Total Debt shows it stood at $809.4 million in 2021, then tumbled by 44.59% to $448.5 million in 2022, then dropped by 0.45% to $446.5 million in 2023, then surged by 48.65% to $663.7 million in 2024, then dropped by 13.8% to $572.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Debt were $572.1 million in Q4 2025, $663.1 million in Q3 2025, and $667.8 million in Q2 2025.